COMydAL Program

We are excited to welcome you to participate in the 1^st World Congress on Controversies in MDS and AML (COMydAL), which will be held virtually over the days of September 22-23, 2022, in parallel with the 2022 IACH Meeting.

This inaugural program will bring to the forefront the latest and most controversial data and information in the field of MDS and AML, providing a unique opportunity for world-class leaders in the field to debate vital issues – thank you for joining!

**All presentations indicated with were available for on demand viewing only until Monday, October 3, 2022* DAY 1 – AML Thursday, September 22, 2022 Co-chairs: Amer Zeidan, USA and Andrew Wei**, Australia
13:15-13:25	Welcome Address
13:25-14:30	Session 1
	Debate: Therapeutic decisions based on MRD in AML: Ready for prime time?
	* Yes: Christopher Hourigan, USA
	No: Christopher Gibson, USA
	Case studies of MRD use for therapeutic decisions in AML: Andrew Wei, Australia
	Panel discussion
14:30-15:35	Session 2
	Debate: Which FLT3 inhibitor to use in frontline therapy in FLT3 mutated AML?
	Midostaurin: Richard Stone, USA
	Quizartinib: Harry Erba, USA
	Case studies of FLT3 inhibitors in AML: Selina Luger, USA
	Panel discussion
15:35-16:45	Session 3
	Debate: Intensive chemotherapy or Ven-based lower intensity regimens for older FIT AML patients?
	* Intensive chemo: Jessica Altman, USA
	Non-intensive chemo: Nicholas Short, USA
	Case studies: Can we cease VEN-AZA in patients in long-term remission? Chong Chyn Chua, Australia
	Panel discussion
16:45-17:50	Session 4
	Debate: Should we use maintenance therapy post allogeneic transplant in AML?
	* Yes: Lohith Gowda, USA
	No: Catherine Lai, USA
	Case studies of how I use maintenance therapies post alloBMT in AML: Asmita Mishra, USA
	Panel discussion
17:50-19:00	Session 5
	Will immune checkpoint inhibition find a way in AML and MDS? Naval Daver, USA
	Will CAR therapies find a way in AML and MDS? Monica Guzman, USA
	Case studies: How I use immune therapies in AML and MDS: Ivana Gojo, USA
	Panel discussion
19:00-20:15	Session 6
	Debate: In 10 years we will cure most AML patients without transplant
	Yes: Tapan Kadia*, USA
	No: Gail Roboz, USA
	* Case studies: How I decide on recommending alloBMT in AML: Michael Heuser, Germany
	Panel discussion

DAY 2 – MDS Friday, September 23, 2022 Co-chairs: Amer Zeidan, USA and Valeria Santini, Italy
11:00-12:10	Session 7
	Debate: Are we ready for clinical trials with triplets in HR-MDS?
	* Yes: Uwe Platzbecker, Germany
	No: Andrew Brunner, USA
	Case studies: When do I use combination therapy in HR-MDS in my clinic? Amy DeZern, USA
	Panel discussion
12:10-13:10	Session 8
	Debate: Overall survival should be the basis of any approval in HR-MDS
	Yes: Uma Borate, USA
	No: Rory Shallis, USA
	Case studies: How do I use “less than CR” responses in HR-MDS in my clinic to direct therapy: Anne Sophie Kubasch, Germany
	Panel discussion
13:10-14:15	Session 9
	Debate: Can observation be a good choice in some cases of higher risk MDS?
	Yes: Valeria Santini, Italy
	No: Pierre Fenaux, France
	Case studies: How do I use observation in management of lower and higher risk MDS? Elizabeth Griffiths, USA
	Panel discussion
	Program pause
16:00-17:05	Session 10
	Debate: Should we give HMA before alloBMT for HR-MDS with 5-9% blasts?
	Yes: Maximilian Stahl, USA
	No: Emanuele Angelucci, Italy
	Case studies: Bridging therapy choices before alloBMT in HR-MDS: Hetty Carraway, USA
	Panel discussion
17:05-18:05	Session 11
	Debate: The primary risk stratification tool in MDS should become IPSS-M
	Yes: Rafael Bejar, USA
	No: Aziz Nazha, USA
	Case studies: How do I use the different MDS stratification tools in my clinic: Aditi Shastri, USA
	Panel discussion
18:05-19:15	Session 12
	Debate: Why do we keep having failed phase 3 trials in HR-MDS?
	Bad drugs: Steven Gore, USA
	Bad trial designs: Mikkael Sekeres, USA
	Overview of exciting drugs in lower and higher risk MDS: Amer Zeidan, USA
	Panel discussion
	Closing Remarks

COMydAL Program

Registration